ABSTRACT
Background Cardiac and inflammatory biomarkers have been associated with adverse outcome after major abdominal surgery. Remote ischemic preconditioning (RIPC) may protect organs from ischemic insults during and after cardiac surgery, but the effect in major abdominal surgery is largely unknown.
Objective To study the effect of RIPC on cardiac and inflammatory biomarkers in patients undergoing pancreatic resection.
Methods Single-center, double-blind, randomized controlled trial in ninety patients undergoing elective pancreatic resection between March 2017 and February 2019. Three cycles of upper-limb ischemia and reperfusion (each 5 minutes) were applied before surgery. The primary endpoint was the maximum postoperative high-sensitive cardiac troponin (hs-cTn) T concentration within 48 hours after surgery. Secondary endpoints were postoperative myocardial injury (PMI, defined as a postoperative hs-cTnT ≥14 ng L-1), the maximum concentration of interleukin (IL)-6 within 48 hours after surgery, and postoperative complications within 30-days of surgery.
Results RIPC did not reduce the maximum hs-cTnT concentration after surgery (12.6 ng L-1 vs 16.6 ng L-1 in the control group (P=0.23), nor did it lessen the incidence of PMI (15 (33.3%) patients in the RIPC group versus 19 (42.2%) controls, P=0.93). The maximum postoperative IL-6 concentration was 239 pg mL-1 [115-360] in the RIPC group, as compared to 317 pg mL-1 [174-909] in the control group (P=0.13). A postoperative complication occurred in 23 (51%) RIPC patients and 24 (53%) controls.
Conclusions Remote ischemic preconditioning did not reduce the maximum postoperative hs-cTnT concentration. Postoperative myocardial injury, IL-6 concentrations and postoperative complications were not statistically different between RIPC patients and controls.
Trial Registration Clinicaltrials.gov identifier NCT03460938
Funding Funding for biomarker analysis was provided by Roche Diagnostics. Roche Diagnostics had no role in design and conduct of the study, analysis and interpretation of the data, preparation and approval of the manuscript.
Strengths and limitations of this study
Well-designed clinical trial in a selected group of high-risk abdominal surgery patients.
Serial assessment of high-sensitive cardiac troponin T and interleukin-6 concentrations.
Postoperative cardiac biomarker concentrations were relatively low.
This trial was not primarily designed to detect differences in IL-6 concentrations and postoperative complications.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03460938
Funding Statement
Funding for biomarker analysis was provided by Roche Diagnostics. Roche Diagnostics had no role in design and conduct of the study, analysis and interpretation of the data, preparation and approval of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Medical research Ethics Committees United (MEC-U, number R16.042)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data access and responsibility The principal investigators Laura van Zeggeren and Peter Noordzij had full access to all of the data in the study and take full responsibility for the integrity of the data and accuracy of the data analysis.
Conflicts of Interest and Source of Funding Dr. Noordzij is a member of the advisory board of Roche Diagnostics on the perioperative use of biomarkers.
Funding for biomarker analysis was provided by Roche Diagnostics. Roche Diagnostics had no role in design and conduct of the study, analysis and interpretation of the data, preparation and approval of the manuscript.
Clinical trial registration The study protocol was registered at clinicaltrials.gov: NCT03460938.
Data Availability
The principal investigators Laura van Zeggeren and Peter Noordzij had full access to all of the data in the study and take full responsibility for the integrity of the data and accuracy of the data analysis.
